Toxicity Profile With a Large Prostate Volume After External Beam Radiotherapy for Localized Prostate Cancer

Pinkawa, Michael; Fischedick, Karin; Asadpour, Branka; Gagel, Bernd; Piroth, Marc D.; Nussen, Sandra; Eble, Michael J.

doi:10.1016/j.ijrobp.2007.05.051

Cited by 47 publications

(48 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Although CTV and PTV did not influence the incidence of adverse events, there are some studies on conventional radiotherapy reporting CTV impact on toxicity [45,46]. It may be influenced by small number of patients with side effects in our group.…”

Section: Discussioncontrasting

confidence: 54%

Acute toxicity of robotic ultrahypofractionated radiotherapy CyberKnifeTM in prostate cancer patients

Głowacki¹,

Majewski²,

Wojcieszek³

et al. 2015

neo

View full text Add to dashboard Cite

Our purpose was to evaluate the toxicity of CyberKnife TM based fractionated stereotactic radiotherapy (FSRT) in prostate cancer patients. One-hunred-thirty-two men with low (62) and intermediate (70) prostate cancer were enrolled in our prospective study. Mean age was 69. Total dose of 36,25 Gy in 5 fractions was prescribed. Image guided FSRT was performed on CyberKnife. Minimum follow-up ranged from 3 to 28 months. EORTC/RTOG scale was used to evaluate toxicity. A total of 47%, 10% and 2% of patients presented grade 1, 2 and 3 acute genitourinary toxicity, respectively. In 25% and 3% of patients, respectively, grade 1 and 2 acute gastrointestinal toxicity was observed. No significant association between acute grade ≥ 2 toxicity and clinical factors: age, androgen deprivation therapy or infections were found. Neither CTV nor PTV volumes had significant impact on acute grade ≥ 2 toxicity. Late toxicity was assessed in 104 patients. In 16% and 1% of patients late GU toxicity in grade 1 and 2, respectively, was presented. Late GI toxicity grade 1, 2 and 3 occurred in 8%, 3% and 1% of patients, respectively. The acute toxicity rates of fractionated stereotactic radiotherapy are low. Early data suggest also low late toxicity rates.

show abstract

Section: Discussioncontrasting

confidence: 54%

Acute toxicity of robotic ultrahypofractionated radiotherapy CyberKnifeTM in prostate cancer patients

Głowacki¹,

Majewski²,

Wojcieszek³

et al. 2015

neo

View full text Add to dashboard Cite

show abstract

“…Pinkawa et al recently addressed acute urinary toxicity in 204 men treated to Ͼ70 Gy with external beam irradiation with special emphasis on pretreatment prostate volume. 81 Side effects were measured at completion of treatment, as well as at 2 and 12 months afterward. One-third of men reported dysuria, and 37% reported obstructive symptoms at completion of treatment.…”

Section: Urinary Functionmentioning

confidence: 99%

Management of Complications of Prostate Cancer Treatment

Michaelson

Cotter

Gargollo

et al. 2008

CA: A Cancer Journal for Clinicians

161

146

View full text Add to dashboard Cite

“…The etiology of radiation-induced dysuria is unknown, but may involve inflammation and mucosal loss at the urethra and bladder neck (6). The risk of dysuria appears to be dependent upon a number of factors, including the prostate volume, the volume of the urethra receiving a high-radiation dose, and delayed use of alpha-blockers (7,8).…”

Section: Sbrt-related Dysuriamentioning

confidence: 99%